Niels van de Donk

PROF.DR., (Principal Investigator)

20122020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

2020

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

Landgren, C. O., Chari, A., Cohen, Y. C., Spencer, A., Voorhees, P., Estell, J. A., Sandhu, I., Jenner, M. W., Williams, C., Cavo, M., van de Donk, N. W. C. J., Beksac, M., Moreau, P., Goldschmidt, H., Kuppens, S., Bandekar, R., Clemens, P. L., Neff, T., Heuck, C., Qi, M. & 1 others, Hofmeister, C. C., 1 Jan 2020, In : Leukemia.

Research output: Contribution to journalArticleAcademicpeer-review

Open Access

Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma

Holthof, L. C., van der Horst, H. J., van Hal-van Veen, S. E., Ruiter, R. W. J., Li, F., Buijze, M., Andersen, M. N., Yuan, H., de Bruijn, J., van de Donk, N. W. C. J., Lokhorst, H. M., Zweegman, S., Groen, R. W. J. & Mutis, T., 1 Jan 2020, In : Haematologica. 105, 2, p. e80-e83

Research output: Contribution to journalLetterAcademicpeer-review

Open Access
2019

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Moreau, P., Attal, M., Hulin, C., Arnulf, B., Belhadj, K., Benboubker, L., Béné, M. C., Broijl, A., Caillon, H. L., Caillot, D., Corre, J., Delforge, M., Dejoie, T., Doyen, C., Facon, T., Sonntag, C. C., Fontan, J., Garderet, L., Jie, K-S., Karlin, L. & 38 others, Kuhnowski, F., Lambert, J. R., Leleu, X., Lenain, P., Macro, M., Mathiot, C., Orsini-Piocelle, F., Perrot, A., Stoppa, A-M., van de Donk, N. W. CJ., Wuilleme, S., Zweegman, S., Kolb, B., Touzeau, C., Roussel, M., Tiab, M., Marolleau, J-P., Meuleman, N., Vekemans, M-C., Westerman, M., Klein, S. K., Levin, M-D., Fermand, J. P., Escoffre-Barbe, M., Eveillard, J-R., Garidi, R., Ahmadi, T., Zhuang, S., Chiu, C., Pei, L., de Boer, C., Smith, E., Deraedt, W., Kampfenkel, T., Schecter, J., Vermeulen, J., Avet-Loiseau, H. & Sonneveld, P., 6 Jul 2019, In : The Lancet. 394, 10192, p. 29-38

Research output: Contribution to journalArticleAcademicpeer-review

Carfilzomib for relapsed and refractory multiple myeloma

Groen, K., van de Donk, N., Stege, C., Zweegman, S. & Nijhof, I. S., 2019, In : Cancer management and research. 11, p. 2663-2675 13 p.

Research output: Contribution to journalReview articleAcademicpeer-review

CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia

Naik, J., Themeli, M., de Jong-Korlaar, R., Ruiter, R. W. J., Poddighe, P. J., Yuan, H., de Bruijn, J. D., Ossenkoppele, G. J., Zweegman, S., Smit, L., Mutis, T., Martens, A. C. M., van de Donk, N. W. C. J. & Groen, R. W. J., 28 Feb 2019, In : Haematologica. 104, 3, p. e100-e103

Research output: Contribution to journalLetterAcademicpeer-review

Open Access

Combined CD28 and 4-1BB costimulation potentiates affinity-tuned chimeric antigen receptor-engineered t cells

Drent, E., Poels, R., Ruiter, R., van de Donk, N. W. C. J., Zweegman, S., Yuan, H., de Bruijn, J., Sadelain, M., Lokhorst, H. M., Groen, R. W. J., Mutis, T. & Themeli, M., 1 Jan 2019, In : Clinical Cancer Research. 25, 13, p. 4014-4025 12 p.

Research output: Contribution to journalArticleAcademicpeer-review

Open Access

Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients

Frerichs, K. A., Bosman, P. W. C., van Velzen, J. F., Fraaij, P. L. A., Koopmans, M. P. G., Rimmelzwaan, G. F., Nijhof, I. S., Bloem, A. C., Mutis, T., Zweegman, S. & van de Donk, N. W. C. J., 26 Sep 2019, In : Haematologica.

Research output: Contribution to journalArticleAcademicpeer-review

Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study

Nielsen, L. K., Stege, C., Lissenberg-Witte, B., van der Holt, B., Mellqvist, U-H., Salomo, M., Bos, G., Levin, M-D., Visser-Wisselaar, H., Hansson, M., van der Velden, A., Deenik, W., Coenen, J., Hinge, M., Klein, S., Tanis, B., Szatkowski, D., Brouwer, R., Westerman, M., Leys, R. & 10 others, Sinnige, H., Haukås, E., van der Hem, K., Durian, M., Gimsing, P., van de Donk, N., Sonneveld, P., Waage, A., Abildgaard, N. & Zweegman, S., 12 Sep 2019, In : Haematologica.

Research output: Contribution to journalArticleAcademicpeer-review

High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action

Adams, H. C., Stevenaert, F., Krejcik, J., Van der Borght, K., Smets, T., Bald, J., Abraham, Y., Ceulemans, H., Chiu, C., Vanhoof, G., Usmani, S. Z., Plesner, T., Lonial, S., Nijhof, I., Lokhorst, H. M., Mutis, T., van de Donk, N. W. C. J., Sasser, A. K. & Casneuf, T., 1 Mar 2019, In : Cytometry Part A. 95, 3, p. 279-289 11 p.

Research output: Contribution to journalArticleAcademicpeer-review

Open Access

Immunotherapy in myeloma: how far have we come?

Franssen, L. E., Mutis, T., Lokhorst, H. M. & van de Donk, N. W. C. J., 2019, In : THERAPEUTIC ADVANCES IN HEMATOLOGY. 10, p. 2040620718822660

Research output: Contribution to journalReview articleAcademicpeer-review

Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma

van de Donk, N. W. C. J., Casneuf, T., Di Cara, A., Parren, P. W., Zweegman, S., van Kessel, B., Lokhorst, H. M., Usmani, S. Z., Lonial, S., Richardson, P. G., Chiu, C., Mutis, T., Nijhof, I. S. & Sasser, A. K., 1 Feb 2019, In : British Journal of Haematology. 184, 3, p. 475-479 5 p.

Research output: Contribution to journalLetterAcademicpeer-review

International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

Hillengass, J., Usmani, S., Rajkumar, S. V., Durie, B. G. M., Mateos, M-V., Lonial, S., Joao, C., Anderson, K. C., García-Sanz, R., Serra, E. R., du, J., van de Donk, N., Berdeja, J. G., Terpos, E., Zamagni, E., Kyle, R. A., San Miguel, J., Goldschmidt, H., Giralt, S., Kumar, S. & 15 others, Raje, N., Ludwig, H., Ocio, E., Schots, R., Einsele, H., Schjesvold, F., Chen, W-M., Abildgaard, N., Lipe, B. C., Dytfeld, D., Wirk, B. M., Drake, M., Cavo, M., Lahuerta, J. J. & Lentzsch, S., 1 Jun 2019, In : The Lancet Oncology. 20, 6, p. e302-e312

Research output: Contribution to journalReview articleAcademicpeer-review

Monoclonal gammopathy of renal significance (MGRS) histopathologic classification, diagnostic workup, and therapeutic options

Amaador, K., Peeters, H., Minnema, M. C., Nguyen, T. Q., Dendooven, A., Vos, J. M. I., Croockewit, A. J., van de Donk, N. W. C. J., Jacobs, J. F. M., Wetzels, J. F. M., Sprangers, B. & Abrahams, A. C., 1 Sep 2019, In : Netherlands Journal of Medicine. 77, 7, p. 243-254

Research output: Contribution to journalArticleAcademicpeer-review

Oral proteasome inhibitor maintenance for multiple myeloma

van de Donk, N. W. C. J. & Yong, K., 19 Jan 2019, In : The Lancet. 393, 10168, p. 204-205

Research output: Contribution to journalComment/Letter to the editorAcademic

Reprint of “Immunomodulatory effects of CD38-targeting antibodies”

van de Donk, N. W. C. J., Jan 2019, In : Immunology Letters. 205, p. 71-77 7 p.

Research output: Contribution to journalReview articleAcademicpeer-review

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma

Usmani, S. Z., Nahi, H., Mateos, M-V., van de Donk, N. W. C. J., Chari, A., Kaufman, J. L., Moreau, P., Oriol, A., Plesner, T., Benboubker, L., Hellemans, P., Masterson, T., Clemens, P. L., Luo, M., Liu, K. & San-Miguel, J., 22 Aug 2019, In : Blood. 134, 8, p. 668-677

Research output: Contribution to journalArticleAcademicpeer-review

2018

A phase II study of selinexor(KPT-330) combined with bortezomib and dexamethasone (SVD) for induction and consolidation for patients with progressive or refractory multiple myeloma: The selvedex trial

Broijl, A., Asselbergs, E. L., Minnema, M. C., Lonergan, S., van der Holt, B., van de Donk, N., Zweegman, S. & Sonneveld, P., 2018, (Congr Eur Hematol Assoc (EHA) SO - Congr Eur Hematol Assoc (EHA))

Research output: Book/ReportBookAcademicpeer-review

Case report: Persistently seronegative neuroborreliosis in an immunocompromised patient

Wagemakers, A., Visser, M. C., de Wever, B., Hovius, J. W., van de Donk, N. W. C. J., Hendriks, E. J., Peferoen, L., Muller, F. F. & Ang, C. W., 2018, In : BMC Infectious Diseases. 18, 1, 362.

Research output: Contribution to journalArticleAcademicpeer-review

Open Access

CD38 antibodies in multiple myeloma: Back to the future

van de Donk, N. W. C. J., Richardson, P. G. & Malavasi, F., 2018, In : Blood. 131, 1, p. 13-29

Research output: Contribution to journalReview articleAcademicpeer-review

CD38 antibodies in multiple myeloma: Mechanisms of action and modes of resistance

van de Donk, N. W. C. J. & Usmani, S. Z., 2018, In : Frontiers in Immunology. 9, SEP, 2134.

Research output: Contribution to journalReview articleAcademicpeer-review

Open Access

CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience

Frerichs, K. A., Nagy, N. A., Lindenbergh, P. L., Bosman, P., Marin Soto, J., Broekmans, M., Groen, R. W. J., Themeli, M., Nieuwenhuis, L., Stege, C., Nijhof, I. S., Mutis, T., Zweegman, S., Lokhorst, H. M. & van de Donk, N. W. C. J., Mar 2018, In : Expert Review of Clinical Immunology. 14, 3, p. 197-206 10 p.

Research output: Contribution to journalArticleAcademicpeer-review

Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients

Franssen, L. E., Nijhof, I. S., Couto, S., Levin, M. D., Bos, G. M. J., Broijl, A., Klein, S. K., Ren, Y., Wang, M., Koene, H. R., Bloem, A. C., Beeker, A., Faber, L. M., van der Spek, E., Raymakers, R., Leguit, R. J., Sonneveld, P., Zweegman, S., Lokhorst, H., Mutis, T. & 3 others, Thakurta, A., Qian, X. & van de Donk, N. W. C. J., 31 Jul 2018, In : Haematologica. 103, 8, p. e368-e371

Research output: Contribution to journalLetterAcademicpeer-review

Open Access

Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update

Nijhof, I. S., van de Donk, N. W. C. J., Zweegman, S. & Lokhorst, H. M., 1 Jan 2018, In : Drugs. 78, 1, p. 19-37 19 p.

Research output: Contribution to journalArticleAcademicpeer-review

Open Access

European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias

Gavriatopoulou, M., Musto, P., Caers, J., Merlini, G., Kastritis, E., van de Donk, N., Gay, F., Hegenbart, U., Hajek, R., Zweegman, S., Bruno, B., Straka, C., Dimopoulos, M. A., Einsele, H., Boccadoro, M., Sonneveld, P., Engelhardt, M. & Terpos, E., 2018, In : Leukemia. 32, 9, p. 1883-1898

Research output: Contribution to journalReview articleAcademicpeer-review

European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when

Caers, J., Garderet, L., Kortüm, K. M., O'Dwyer, M. E., van de Donk, N. W. C. J., Binder, M., Dold, S. M., Gay, F., Corre, J., Beguin, Y., Ludwig, H., Larocca, A., Driessen, C., Dimopoulos, M. A., Boccadoro, M., Gramatzki, M., Zweegman, S., Einsele, H., Cavo, M., Goldschmidt, H. & 5 others, Sonneveld, P., Delforge, M., Auner, H. W., Terpos, E. & Engelhardt, M., 2018, In : Haematologica. 103, 11, p. 1772-1784

Research output: Contribution to journalArticleAcademicpeer-review

Open Access

Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design

Drent, E., Poels, R., Mulders, M. J., van de Donk, N. W. C. J., Themeli, M., Lokhorst, H. M. & Mutis, T., 2018, In : PLoS ONE. 13, 5, p. e0197349

Research output: Contribution to journalArticleAcademicpeer-review

Open Access

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives

Gay, F., Engelhardt, M., Terpos, E., Wäsch, R., Giaccone, L., Auner, H. W., Caers, J., Gramatzki, M., van de Donk, N., Oliva, S., Zamagni, E., Garderet, L., Straka, C., Hajek, R., Ludwig, H., Einsele, H., Dimopoulos, M., Boccadoro, M., Kröger, N., Cavo, M. & 3 others, Goldschmidt, H., Bruno, B. & Sonneveld, P., Feb 2018, In : Haematologica. 103, 2, p. 197-211 15 p.

Research output: Contribution to journalReview articleAcademicpeer-review

Open Access

Immunomodulatory effects of CD38-targeting antibodies

van de Donk, N. W. C. J., 2018, In : Immunology Letters. 199, p. 16-22

Research output: Contribution to journalReview articleAcademicpeer-review

Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients

Franssen, L. E., Nijhof, I. S., Bjorklund, C. C., Chiu, H., Doorn, R., Van Velzen, J., Emmelot, M., Van Kessel, B., Levin, M. D., Bos, G. M. J., Broijl, A., Klein, S. K., Koene, H. R., Bloem, A. C., Beeker, A., Faber, L. M., Van Der Spek, E., Raymakers, R., Sonneveld, P., Zweegman, S. & 5 others, Lokhorst, H. M., Thakurta, A., Qian, X., Mutis, T. & Van De Donk, N. W. C. J., 1 Sep 2018, In : Oncotarget. 9, 74, p. 34009-34021 13 p.

Research output: Contribution to journalArticleAcademicpeer-review

Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and renal impairment: Results from a phase ii trial

Dimopoulos, M., Weisel, K., van de Donk, N. W. C. J., Ramasamy, K., Gamberi, B., Streetly, M., Offidani, M., Bridoux, F., de la Rubia, J., Mateos, M-V., Ardizzoia, A., Kueenburg, E., Collins, S., di Micco, A., Rosettani, B., Li, Y., Bacon, P. & Sonneveld, P., 2018, In : Journal of Clinical Oncology. 36, 20, p. 2035-2043

Research output: Contribution to journalArticleAcademicpeer-review

Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network

Ludwig, H., Delforge, M., Facon, T., Einsele, H., Gay, F., Moreau, P., Avet-Loiseau, H., Boccadoro, M., Hajek, R., Mohty, M., Cavo, M., Dimopoulos, M. A., San-Miguel, J. F., Terpos, E., Zweegman, S., Garderet, L., Mateos, M-V., Cook, G., Leleu, X., Goldschmidt, H. & 12 others, Jackson, G., Kaiser, M., Weisel, K., van de Donk, N. W. C. J., Waage, A., Beksac, M., Mellqvist, U. H., Engelhardt, M., Caers, J., Driessen, C., Bladé, J. & Sonneveld, P., 2018, In : Leukemia. 32, 7, p. 1542-1560

Research output: Contribution to journalReview articleAcademicpeer-review

Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial

van de Donk, N. W. CJ., van der Holt, B., Minnema, M. C., Vellenga, E., Croockewit, S., Kersten, M. J., von dem Borne, P. A., Ypma, P., Schaafsma, R., de Weerdt, O., Klein, S. K., Delforge, M., Levin, M-D., Bos, G. M., Jie, K-S. G., Sinnige, H., Coenen, J. L. LM., de Waal, E. G., Zweegman, S., Sonneveld, P. & 1 others, Lokhorst, H. M., 2018, In : The Lancet Haematology. 5, 10, p. e479-e492

Research output: Contribution to journalArticleAcademicpeer-review

2017

A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma

Franssen, L. E., Roeven, M. W. H., Hobo, W., Doorn, R., Oostvogels, R., Falkenburg, J. H. F., Van De Donk, N. W., Kester, M. G. D., Fredrix, H., Westinga, K., Slaper-Cortenbach, I., Spierings, E., Kersten, M. J., Dolstra, H., Mutis, T., Schaap, N. & Lokhorst, H. M., 1 Oct 2017, In : Bone Marrow Transplantation. 52, 10, p. 1378-1383 6 p.

Research output: Contribution to journalArticleAcademicpeer-review

A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization

Drent, E., Themeli, M., Poels, R., de Jong-Korlaar, R., Yuan, H., de Bruijn, J., Martens, A. C. M., Zweegman, S., van de Donk, N. W. C. J., Groen, R. W. J., Lokhorst, H. M. & Mutis, T., 2 Aug 2017, In : Molecular Therapy. 25, 8, p. 1946-1958 13 p.

Research output: Contribution to journalArticleAcademicpeer-review

Carfilzomib versus bortezomib: no longer an ENDEAVOR

van de Donk, N. WCJ., 1 Oct 2017, In : The Lancet Oncology. 18, 10, p. 1288-1290 3 p.

Research output: Contribution to journalComment/Letter to the editorAcademic

Could daratumumab be used to treat severe allergy?

Blankestijn, M. A., van de Donk, N. W. C. J., Sasser, K., Knulst, A. C. & Otten, H. G., May 2017, In : Journal of Allergy and Clinical Immunology. 139, 5, p. 1677-1678.e3

Research output: Contribution to journalArticleAcademicpeer-review

Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma

Casneuf, T., Xu, X. S., Adams, H. C., Axel, A. E., Chiu, C., Khan, I., Ahmadi, T., Yan, X., Lonial, S., Plesner, T., Lokhorst, H. M., van de Donk, N. W. C. J., Clemens, P. L. & Sasser, A. K., 24 Oct 2017, In : Blood. 1, 23, p. 2105-2114 10 p.

Research output: Contribution to journalArticleAcademicpeer-review

FEASIBILITY AND EFFICACY OF DOSE ADJUSTED MELPHALAN - PREDNISONE - BORTEZOMIB IN PATIENTS >= 75 YEARS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; PRELIMINARY RESULTS OF THE PHASE II HOVON 123 STUDY

Zweegman, S., Levin, M. -D., Klein, S. K., de Waal, E. G., Eeltink, C. M., Ypma, P. F., Dijk, A. C., Westerman, M., Deenik, W., Tanis, B., Slee-Valentijn, M. S., Minnema, M. C., Visser-Wisselaar, H., Stege, C., van de Donk, N. W., Nasserinejad, K. & Sonneveld, P., 26 Jun 2017, In : Haematologica. 102, p. 112-113

Research output: Contribution to journalMeeting AbstractAcademic

Frailty predicts survival and toxicity in newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation; report of the HOVON-87/NMSG-18 study group

Stege, C. A. M., Van Der Holt, B., Mellqvist, U. H., Levin, M. D., Salomo, M., Abildgaard, N., Bos, G., Visser-Wisselaar, H., Hansson, M., Van Der Velden, A., Deenik, W., Gruber, A., Coenen, J. L. L. M., Plesner, T., Klein, S., Tanis, B., Szatkowski, D. L., Brouwer, R., Westerman, M., Leijs, M. B. & 11 others, Sinnige, H., Haukaas, E., Van Der Hem, K., Durian, M., Mattijssen, V., Gimsing, P., Van De Donk, N. W. C. J., Stevens-Kroef, M., Sonneveld, P., Waage, A. & Zweegman, S., 2017, Blood. Conference: 59th Annual Meeting of the American Society of Hematology, ASH. (Blood. Conference: 59th Annual Meeting of the American Society of Hematology, ASH; vol. 130).

Research output: Chapter in Book/Report/Conference proceedingChapterAcademicpeer-review

High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation

Cook, G., Iacobelli, S., van Biezen, A., Ziagkos, D., LeBlond, V., Abraham, J., McQuaker, G., Schoenland, S., Rambaldi, A., Halaburda, K., Rovira, M., Sica, S., Byrne, J., Sanz, R. G., Nagler, A., van de Donk, N. W. C. J., Sinisalo, M., Cook, M., Kröger, N., De Witte, T. & 2 others, Morris, C. & Garderet, L., Jan 2017, In : Haematologica. 102, 1, p. 160-167 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab

Krejcik, J., Frerichs, K. A., Nijhof, I. S., van Kessel, B., van Velzen, J. F., Bloem, A. C., Broekmans, M. E. C., Zweegman, S., van Meerloo, J., Musters, R. J. P., Poddighe, P. J., Groen, R. W. J., Chiu, C., Plesner, T., Lokhorst, H. M., Sasser, A. K., Mutis, T. & van de Donk, N. W. C. J., 15 Dec 2017, In : Clinical Cancer Research. 23, 24, p. 7498-7511 14 p.

Research output: Contribution to journalArticleAcademicpeer-review

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study

Kumar, S. K., Dimopoulos, M. A., Kastritis, E., Terpos, E., Nahi, H., Goldschmidt, H., Hillengass, J., Leleu, X., Beksac, M., Alsina, M., Oriol, A., Cavo, M., Ocio, E. M., Mateos, M. V., O'Donnell, E. K., Vij, R., Lokhorst, H. M., Van De Donk, N. W. C. J., Min, C., Mark, T. & 27 others, Turesson, I., Hansson, M., Ludwig, H., Jagannath, S., Delforge, M., Kyriakou, C., Hari, P., Mellqvist, U., Usmani, S. Z., Dytfeld, D., Badros, A. Z., Moreau, P., Kim, K., Otero, P. R., Lee, J. H., Shustik, C., Waller, D., Chng, W. J., Ozaki, S., Lee, J. J., De La Rubia, J., Eom, H. S., Rosinol, L., Lahuerta, J. J., Sureda, A., Kim, J. S. & Durie, B. G. M., 1 Nov 2017, In : Leukemia. 31, 11, p. 2443-2448 6 p.

Research output: Contribution to journalArticleAcademicpeer-review

Primary cardiac lymphoma with central nervous system relapse

van Rooijen, C. R., Scholtens, A. M., de Jong, C. N., Saraber, C. E. & van de Donk, N. W. C. J., Sep 2017, In : Clinical case reports. 5, 9, p. 1454-1458 5 p.

Research output: Contribution to journalArticleAcademicpeer-review

Response to: Interference of daratumumab on the serum protein electrophoresis

McCudden, C., Axel, A. E., Slaets, D., Dejoie, T., Clemens, P., Frans, S., Bald, J., Plesner, T., Jacobs, J. F. M., van de Donk, N. W. C. J., Moreau, P., Schecter, J. M., Ahmadi, T. & Sasser, A. K., 1 Feb 2017, In : Clinical Chemistry and Laboratory Medicine. 55, 2, p. e29-e30

Research output: Contribution to journalArticleAcademicpeer-review

2016

A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma

Franken, B., van de Donk, N. W. C. J., Cloos, J. C., Zweegman, S. & Lokhorst, H. M., Dec 2016, In : THERAPEUTIC ADVANCES IN HEMATOLOGY. 7, 6, p. 330-344

Research output: Contribution to journalArticleAcademicpeer-review

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

Nijhof, I. S., Casneuf, T., van Velzen, J., van Kessel, B., Axel, A. E., Syed, K., Groen, R. W. J., van Duin, M., Sonneveld, P., Minnema, M. C., Zweegman, S., Chiu, C., Bloem, A. C., Mutis, T., Lokhorst, H. M., Sasser, A. K. & van de Donk, N. W. C. J., 18 Aug 2016, In : Blood. 128, 7, p. 959-970

Research output: Contribution to journalArticleAcademicpeer-review

Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma

van de Donk, N. W. C. J., Moreau, P., Plesner, T., Palumbo, A., Gay, F., Laubach, J. P., Malavasi, F., Avet-Loiseau, H., Mateos, M-V., Sonneveld, P., Lokhorst, H. M. & Richardson, P. G., 11 Feb 2016, In : Blood. 127, 6, p. 681-695

Research output: Contribution to journalArticleAcademicpeer-review

Daratumumab depletes CD38(+) immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

Krejcik, J., Casneuf, T., Nijhof, I. S., Verbist, B., Bald, J., Plesner, T., Syed, K., Liu, K., van de Donk, N. W. C. J., Weiss, B. M., Ahmadi, T., Lokhorst, H. M., Mutis, T. & Sasser, A. K., 21 Jul 2016, In : Blood. 128, 3, p. 384-394

Research output: Contribution to journalArticleAcademicpeer-review